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ORIGINAL BASIC SCIENCE STUDIES
A model of in vivo human venous
thrombosis that confirms changes 
in the release of specific soluble cell
adhesion molecules in experimental
venous thrombogenesis
John Quarmby, FRCS, Alberto Smith, PhD, Michael Collins, Stewart
Cederholm-Williams, DPhil, and Kevin Burnand, MS, FRCS, London, United
Kingdom 
Purpose: The mechanisms of venous thrombogenesis have been studied by using animal
models and cells in culture. The results from these systems may not, however, be rele-
vant to the human condition. The aim of this study was to develop a method by which
thrombus could be safely produced in a human vein in vivo. The model that was devel-
oped was used as a means of studying the changes in soluble adhesion molecule expres-
sion in human venous thrombogenesis. 
Methods: An autologous thrombin extract was used to generate experimental thrombi in
the disconnected portion of the long saphenous veins of 30 patients who were under-
going routine bilateral varicose vein surgery. The contralateral vein was perfused with
thrombin extract diluent buffer to act as the control. The concentration of soluble P-,
E- and L-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhe-
sion molecule-1 were measured by means of specific enzyme-linked immunosorbent
assays in samples of blood taken from veins in which thrombus had formed and in con-
tralateral control veins.
Results: Thrombosis invariably formed when at least 100 IU of thrombin activity was
administered. Thrombus formation was independent of the time that the thrombin
extract was allowed to remain within the emptied vessel. Thrombosis never developed in
control vessels that were similarly treated with the buffer used to dilute the thrombin
extract. Experimental thrombi were composed mainly of red cells, with layers of fibrin
next to platelet and leukocyte packages. These findings are similar to those observed in
samples of established human venous thrombi. There were small but significantly high-
er levels of the adhesion molecules, soluble P-selectin, and vascular cell adhesion mole-
cule-1 in blood taken from veins in which experimental thrombi had formed, compared
with controls (P = .015 and .007, respectively; Wilcoxon signed rank test). Serum levels
of soluble L-selectin, E-selectin, and ICAM-1 were not affected by thrombosis.
Conclusion: This model is safe and reproducible. It produces thrombi with a morpholo-
gy similar to that described for established human deep venous thrombi. The model may
be appropriate for the study of the early changes that occur during human venous
thrombogenesis and may also be of value in testing the efficacy of novel antithrombot-
ic agents. (J Vasc Surg 1999;30:139-47.)
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The pathogenesis of venous thrombosis has been
studied with animal models, in vitro systems (such as
the Chandler loop), and endothelial cells in culture.1-3
In vitro methods may afford useful information on
particular mechanisms, but do not provide the same
complex and dynamic environment that exists in vivo,
and their results do not always correlate with findings
from in vivo studies.4,5 Animal models of venous
thrombosis, developed to address this problem, all
alter one or more of “Virchow’s Triad” of factors (sta-
sis, hypercoagulability, and endothelial disturbance)
to stimulate thrombus formation. Various methods,
including complete occlusion of blood flow,6 inser-
tion of wool or silk threads,7 and overt endothelial
damage produced by mechanical,8 electrical,9 or
chemical10 means, have been used to induce throm-
bosis. These conditions seldom occur in patients who
have deep vein thrombosis, and therefore, the experi-
mental “thrombi” formed in these circumstances may
be produced by different mechanisms and have a dif-
ferent composition and structure than human deep
vein thrombi.11 The sequence of events that occurs
during their formation may, therefore, not reflect
those of human thrombogenesis. 
Attempts have been made to simulate the condi-
tions in humans by infusing naturally occurring pro-
coagulants such as thrombin11 and tissue factor12 in
the presence of reduced blood flow, without pro-
ducing overt physical damage to the endothelium.
Primate models have more recently been developed
to overcome the objections that there are marked
differences between the fibrinolytic and thrombotic
processes of humans and other animals13,14; but the
study of thrombosis with these animals is restricted
by cost and ethical considerations. 
Thrombosis is thought to involve interactions
among endothelial cells, platelets, and leukocytes14-17
mediated by cell adhesion molecules produced by
each cell-type.18,19 Leukocyte adhesion and migration
through the vessel wall, resulting in endothelial dam-
age and desquamation, has been postulated to be an
initiating mechanism in venous thrombosis.17 It is
possible, therefore, that there may be changes in the
release of molecules that facilitate these processes
when thrombosis occurs. A thrombosis model in the
baboon has already shown that inhibition of P-
selectin prevents venous thrombosis.14
The aim of this study was to develop a repro-
ducible model of venous thrombosis in humans that
was safe and acceptable to volunteers and to use this
model to investigate whether changes occur in
release of soluble cell adhesion molecules during
early thrombogenesis.
METHODS
Autologous thrombin preparation. Thrombin
was extracted from the patient’s own blood. The
extraction was carried out with aseptic conditions the
day before surgery. Plasma was obtained from 15 mL
of citrated whole blood. A 6-mL aliquot of plasma
was added to 44 mL of 0.04% acetic acid in a conical
polypropylene tube. The mixture was gently agitated
and allowed to stand at room temperature for 5 min-
utes. The protein precipitate formed was centrifuged
at 1500 g for 15 minutes at 10°C. The supernatant
was decanted, and the precipitate was dissolved in 1
mL of an aqueous solution, which contained 0.9%
sodium chloride, 0.03% sodium bicarbonate, and 25
mmol/L calcium chloride (thrombin extract diluent
buffer). The solution was vortexed and allowed to
stand for at least 1 hour to allow fibrin clot forma-
tion. The extract containing clot was decanted onto
a polyurethane sponge placed in a 2.5-mL poly-
styrene syringe. The plunger was replaced and used
to expel the soluble extract through the sponge, leav-
ing the insoluble fibrin adherent to it. The extract
was collected into a sterile 1.5-mL eppendorf tube
and stored at 4°C overnight. 
Thrombin activity was assayed in a 50-m L aliquot
of this extract by measuring fibrin clot formation
time in the presence of excess (3 mg/mL) human
fibrinogen (Sigma, Poole, United Kingdom). Clot
formation time was measured on a KC10 fibrinome-
ter (Behring). 
All preparations were carried out aseptically in a
sterile hood with sterile reagents provided by the
hospital Pharmacy Quality Control Unit.
Surgical procedure. The model was approved by
the St Thomas’ Hospital Ethics Committee. Informed
consent was obtained from patients undergoing bilat-
eral varicose vein surgery (EC95/001). Standard sur-
gical techniques, normally used when exposing the
saphenofemoral junction in the groin as part of routine
bilateral high saphenous ligation for the treatment of
varicose veins, were used to expose the veins. While
patients were under general anesthesia, a groin crease
incision of between 5 and 10 cm, depending on the
build of the patient, was made. The saphenofemoral
junction was carefully dissected out, and as much of
the long saphenous vein as possible was exposed,
avoiding any stretching of the vein. At the saphe-
nofemoral junction, there are usually four to six small
tributaries that join the long saphenous vein just
before it joins the femoral vein. One of these veins
(usually the superficial inferior epigastric vein) was
selected as the outflow to the model, divided, cannu-
lated, and left to bleed in a controlled manner (Fig 1).
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The remaining veins, including the saphenofemoral
junction itself, were tied with 2-0 Vicryl and divided in
the usual way. Blood could only flow out of the vein
through the cannulated tributary selected as the out-
flow, thus ensuring that no recirculation was possible.
The long saphenous vein itself acted as the inflow to
the experimental venous segment. A tributary of this
vein (usually the posteromedial thigh vein) was
exposed through the same groin incision and selected
as the infusion port. This tributary was cannulated and
autologous thrombin extract (approximately 500 m L)
was infused while the distal saphenous vein was isolat-
ed from the circulation by gentle occlusion with a
sling. The thrombin extract was left in situ for a speci-
fied time, then the sling was removed, and blood was
allowed to flow slowly through the experimental seg-
ment of vein. The flow rate was maintained between 2
to 5 mL/min by restricting the outflow. The experi-
mental segment of the long saphenous vein was
removed after 12 minutes. The contralateral long
saphenous vein acted as the control and was vein-
infused with thrombin extract diluent buffer instead of
the thrombin extract. It was otherwise treated in the
same manner as the experimental vein by a second sur-
geon. After the vein segment was removed, the opera-
tion proceeded as planned.
Blood collection and assay. Blood samples were
obtained from the experimental veins of 12 patients 10
minutes after injection of 200 (sd 55) IU of thrombin
activity. Samples were also taken from the contralater-
al veins 10 minutes after injection of thrombin extract
diluent buffer (controls). Plasma and serum samples
were obtained by centrifugation, snap frozen in liquid
nitrogen, and stored at –80°C until assayed. The solu-
ble adhesion molecules—P-selectin (n = 9), E-selectin
(n = 12), L-selectin (n = 12), intercellular adhesion
molecule 1 (ICAM-1; n = 12), and VCAM-1(n =
11)—were assayed with enzyme-linked immunosor-
bent assay kits from R&D Systems (UK).
Titration experiments. Crude thrombin extracts
containing 25 to 300 IU/ m L of thrombin activity
were injected into isolated distal saphenous veins from
30 patients. The extract was allowed to remain with-
in the lumen of the veins for 20 to 180 seconds. This
was carried out to determine the amount of thrombin
activity and contact time required to generate throm-
bi reproducibly. The contralateral veins were given
thrombin diluent buffer only and acted as controls.
Wash-out experiments. Thrombin (200 IU in
300 to 500 m L) was infused into the veins of five
patients and allowed to remain in the vessel for 60 to
120 seconds. The vessels were then flushed with 10
mL of carrier buffer before the restoration of blood
flow. Control veins were infused with thrombin
extract diluent buffer in place of thrombin extract
before blood flow was restored.
Tissue sample processing. Harvested veins
were carefully rinsed in Hartman’s solution before
being placed in either 4% formaldehyde for subse-
quent light microscopy or in 2% glutaraldehyde for
electron microscopy. After fixation, veins were divid-
ed into four segments, which were then processed for
embedding in paraffin wax or epoxy resin. Samples of
veins containing established in vivo thrombus were
obtained from amputated limbs from patients with
known venous thrombosis. These were treated in the
same manner as experimental veins.
Histology. The presence of thrombus in the
veins was assessed by an independent observer with
routine hematoxylin and eosin staining of transverse
paraffin sections taken from each of the four seg-
ments of experimental and control veins. The com-
position of the experimental thrombi, clotted blood,
and human venous thrombi were studied with light
and scanning electron microscopy. The experimental
thrombi were characterized by using Martius scarlet
blue (MSB) staining (which shows fibrin as pink/red,
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Fig 1. Schematic representation of the surgical procedure
used in the in vivo human model of venous thrombosis.
collagen as blue, red cells as yellow, and smooth mus-
cle as red), and immunohistochemistry with anti-fib-
rin and anti-platelet antibodies.
Paraffin sections were trypsinized in 0.1% trypsin
and 0.1% calcium chloride at 37°C for 10 minutes.
The sections were rinsed in a buffer comprising phos-
phate buffered saline, 1% ovalbumin, and 0.05%
Tween, with a pH of 7.4 (incubation buffer).
Sections were then incubated overnight at 4°C with
a monoclonal antibody raised against human platelets
(CD41a, Dako, UK) diluted in the rinse buffer.
Primary antibody binding was located with a biotiny-
lated secondary antibody (rabbit anti-mouse)/alka-
line phosphatase streptavidin complex (Dako).
Statistical analysis. A Wilcoxon signed rank test
was used to determine the significance of the differ-
ences in the concentrations of soluble cell adhesion
molecules. This test was selected because of the diffi-
culty in establishing whether there was a normal dis-
tribution in the small numbers of blood samples taken
from experimental and contralateral control veins. 
RESULTS
Thrombus was always found in veins in which
100 IU or more of thrombin had been infused (Fig
2). Thrombus formation was independent of the
contact time between thrombin and the vessel
endothelium. No thrombus was ever detected in
control veins into which thrombin diluent buffer
had been injected. 
Thrombus was also consistently found in veins
that had been gently flushed with 10 mL of carrier
buffer after injection of 200 IU thrombin and before
resumption of blood flow in five subjects. Thrombus
did not form in the contralateral control veins treat-
ed in the same manner with thrombin carrier buffer
without thrombin.
Histology. The experimental thrombi were
demonstrated by means of MSB and immunohisto-
chemical staining to consist mainly of red cells and
fibrin-platelet layers, which were invariably associat-
ed with leukocytes (Fig 3A and B). This resembles
the structure seen in established venous thrombi
taken from amputated legs (Fig 3C and D). In con-
trast, clotted blood consists of a more homogenous
red cell mass, with an absence of fibrin layering (Fig
3E). The few leukocytes that were present were ran-
domly dispersed throughout the clot. A similar red
cell clot was observed in the valve cusps, when these
were present in the segment in which thrombus was
induced (Fig 3F). Fig 4A shows a low-power scan-
ning electron micrograph of a transverse view of a
saphenous vein containing experimental thrombus
within its lumen. A higher power scanning electron
micrograph of the edge and surface of an experi-
mental thrombus shows evidence of red cells trapped
between fibrin layers and what appear, from their
size, to be leukocytes (possibly monocytes) adherent
to the surface of the thrombus (Fig 4B). High-
power scanning electron micrographs of areas with-
in experimental thrombi show red cells, activated
platelets, and white cells sitting on or within a lattice
work of fibrin (Fig 4C). Fig 4D shows a low-power
micrograph of a transverse section of a vein infused
with thrombin extract diluent buffer only. No
thrombus formation was ever found in these veins.
Higher power micrographs taken of the endothelial
surface of control vessels show some fibrin deposi-
tion and red cell and platelet adhesion, but no evi-
dence of gross endothelial damage caused by the
surgical procedures or diluent buffer used in this
model (Fig 4E and F).
Blood soluble cell adhesion molecule. There
were small but significant differences in the concen-
trations of P-selectin and VCAM-1 in blood samples
taken from experimental veins 10 minutes after
thrombin extract injection compared with levels
found in blood samples obtained from the contralat-
eral control veins similarly treated, but with throm-
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Fig 2. The effect of autologous thrombin activity and
thrombin extract-endothelium contact time on experi-
mental thrombus formation.
bin extract diluent buffer instead of thrombin extract
(Table I). There were no significant differences in the
blood levels of soluble E- or L-selectin and ICAM-1.
There was no difference in these results when
blood levels of E- and L-selectin, ICAM-1, and
VCAM-1 were compared in control and experimen-
tal veins from the nine patients in whom P-selectin
was measured.
DISCUSSION
The model of in vivo human venous thrombosis
described had to be both reproducible and ethically
acceptable (safe in use and agreeable to volunteers).
Several precautions were taken to satisfy the main con-
sideration that the model should not pose a risk to vol-
unteers. First, thrombus was generated in the proximal
end of the long saphenous veins of patients admitted
for bilateral varicose vein surgery, by using a procedure
previously shown to produce thrombosis in a rat vena
cava model of this condition.11 These veins are rou-
tinely excluded from the circulation, thus preventing
entry of infused substances into the systemic circula-
tion. Next, autologous thrombin was used to induce
thrombosis. This removed the possibility of infections
from blood-derived products, such as human immu-
nodeficiency virus, hepatitis B, and hepatitis C. All
preparations were carried out aseptically with sterile
reagents. The absence of any infections in the consid-
erable number of experimental procedures performed
so far, confirms our aseptic technique. Finally, bilateral
varicose vein surgery is often performed by a single
surgeon. In this experimental procedure, two surgeons
were always used, which ensured that operation times
were not excessive.
Histological examination, by means of both light
and electron microscopy, showed that the early
experimental thrombi formed in the human model
were morphologically distinct from clotted blood.
The thrombi were composed of red cells with fibrin
and platelet pockets or layers. Leukocytes were
found mainly in association with the platelets and
fibrin. Despite the use of a superficial vein for this
model, the morphology of the experimental throm-
bi produced was similar to that found in specimens
of deep venous thrombosis. Thrombus that formed
in the valves of the experimental veins consisted pre-
dominantly of red cells. It has previously been sug-
gested that eddy currents, formed in the blood as it
passes a valve, are responsible for turbulence that
leads to a sifting out of the formed elements of a
thrombus, especially the red cells.20
The model was highly reproducible, with throm-
bus always developing in veins infused with at least
100 IU of autologous thrombin activity. Thrombus
formation was dependent on the thrombin dose and
not the contact time between thrombin extract and
the vessel endothelium. 
It is possible that thrombosis occurred because
unbound thrombin activity remained in the vessel
lumen when blood flow was resumed. Flushing the
segment of vein before resumption of blood flow with
an amount of carrier buffer at least 20 times the volume
of thrombin extract used did not, however, inhibit
thrombus formation. This suggests that thrombin may
have been bound by the vessel wall. A specific receptor
for thrombin is known to exist on the surface of a vari-
ety of cell types, including endothelium, platelets,
leukocytes, and smooth muscle cells.21,22 The receptor
is thought to act as a substrate for thrombin and does
not facilitate the cleavage of fibrinogen.21 Bound
thrombin cleaves the amino terminus of the receptor
and produces a tethered peptide ligand that effects
receptor activation.19 In endothelial cells, this activa-
tion may lead to the production of procoagulant pro-
teins, such as platelet activating factor and plasminogen
activator inhibitor, and decrease production of antico-
agulant proteins, such as thrombomodulin.23-25 This
process is unlikely, however, to have a role in the gen-
eration of thrombus in this model, because thrombi
formed within a relatively short period. 
Thrombin is also known to cause the rapid retrac-
tion of endothelial cells in vitro.26,27 Coagulation
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Table I. Soluble cell adhesion molecule concentrations in blood samples obtained from control and experi-
mental veins in which thrombus had developed
P-selectin E-selectin L-selectin ICAM-1 VCAM-1
C EX C EX C EX C EX C EX
Mean concentration 107 121 40 39 742 695 184 184 372 483
(ng/mL)
SD 23 33 14 15 95 92 181 200 181 213
P value .015 (n = 9) .24 (n = 12) .5 (n = 12) .66 (n = 12) .007 (n = 11)
C, Control; EX, experimental; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule-1.
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Fig 3. Morphology of experimental thrombus and established human venous thrombi. A,
Martius scarlet blue stain of experimental (original magnification, 200· ) and C, established
(original magnification, 100· ) venous thrombi showing fibrin as red and red cells as yellow
(dark blue/purple cells in the thrombus indicate leukocytes). B, Localization of platelets in
experimental and D, established thrombi by using the CD41 marker (original magnification,
100· ). E, Martius scarlet blue staining of clotted blood (original magnification, 200· ) and F,
clot within the valve cusp (original magnification, 100· ). 
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Fig 4. Scanning electron microscopy of experimental thrombus. A, Transverse section of
saphenous vein containing thrombus (t; original magnification, 50· ). B, Edge (e) and surface
(s) of the thrombus (original magnification, 400· ). C, Fibrin, red cell, and platelet components
within the thrombus (original magnification, 1000· ). D, Transverse section of contralateral
control vein without thrombus (original magnification, 17· ). E and F, Low- (original magni-
fication, 500· ) and high-power (original magnification, 4000· ) micrographs of control vessel
endothelium.
A B
C D
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could then be initiated by either contact of the blood
with procoagulant proteins, such as tissue factor and
collagen, on the subendothelial matrix or by throm-
bin bound directly to subendothelial proteins.
Thrombin contains amino acid sequences (arginine-
glycine-aspartic acid, RGD) that have been shown to
bind to extracellular matrix proteins in vitro.28
Thrombin bound in this way remained active and
could not be inhibited by its main circulating
inhibitor, antithrombin III.28 No changes in the
endothelial lining of the rabbit neck vein have, how-
ever, been found after in vivo treatment with throm-
bin concentrations as high as 40 U/mL.29 It is pos-
sible that the thrombin stimulus used to promote
thrombus development in these experiments bears
little relation to human thrombosis. It remains to be
seen, however, whether the high thrombin concen-
trations shown to induce thrombus formation in our
model (200 to 300 IU/mL) reflect in vivo condi-
tions (in particular, the microenvironment at the
endothelial cell surface) and whether these concen-
trations could have disrupted the human vascular
endothelium sufficiently to expose the procoagulant
subendothelial matrix proteins. Endothelial cell
retraction could not be properly investigated in this
model, because vein segments could not be perfuse-
fixed at venous pressure in situ. 
The mechanism by which thrombin induces
thrombosis in this model remains to be defined.
Studies using immunohistology, labeled thrombin and
specific thrombin (binding site and active site)
inhibitors, thrombin receptor inhibitors, and RGD
sequence binding inhibitors may help to determine the
contribution of the thrombin receptor and of other
constituents in the crude thrombin extract to throm-
bus generation in this model. More detailed studies
with electron microscopy may also provide an insight
into whether the human vascular endothelium is dis-
rupted by the activity of thrombin in vivo. The possi-
bility that thrombosis was induced by an agent other
than thrombin present in the crude acid extract cannot
be dismissed and also warrants further investigation.
The small but significant difference in the levels
of soluble P-selectin found in blood samples taken
from the thrombin extract-treated veins and con-
tralateral controls support the data from animal
studies that suggested that P-selectin may have a role
as a mediator in early venous thrombosis.14,16,18
Infusion of an anti-P-selectin monoclonal antibody
has been shown to inhibit thrombus formation and
extension in a primate model of venous thrombo-
sis.31 P-selectin is produced and stored in Weibel-
Palade bodies in endothelial cells and in a -granules
in platelets, and it is rapidly translocated to the cell
surface when these cells are stimulated by throm-
bin.30,31 This molecule promotes rolling of leuko-
cytes on the endothelium and the interaction of
leukocytes with platelets.19 Leukocyte diapedesis has
been postulated as a possible nidus for thrombus
formation.17 P-selectin, present on the surface of
transfected cells, has also been shown to up regulate
tissue factor expression in adherent monocytes and
may also promote thrombosis in this way.32
The increased levels of soluble VCAM-1 in blood
samples from treated veins found in this study were
unexpected. This molecule is not stored, but is nor-
mally expressed by endothelial cells and monocytes
activated by substances such as thrombin.19 It is pos-
sible that the differences in soluble VCAM-1 levels
found in blood samples obtained from thrombin
extract-treated and control veins in this study repre-
sents shedding of VCAM-1 already present on the
cell surface, because the process of synthesis would
normally take several hours.19 Increased VCAM-1
release may, therefore, be the product of acute
endothelial cell activation. Binding of VCAM-1 to its
counter receptor very late activation antigen-4 (VLA-
4) is thought to be a mechanism by which leukocytes
firmly adhere to the endothelium before migration in
inflammatory situations.19 The role of this molecule
in thrombogenesis requires further investigation.
As thrombosis develops, other soluble adhesion
molecules may be released. Unfortunately, the nature
of our model only affords a short observation window
through which the early stages of thrombus formation
can be studied. This may explain why changes were not
found in the other adhesion molecules that were test-
ed. The expression of E-selectin is thought to be influ-
enced mainly by cytokines, and the expression of
ICAM-1 is only up regulated within a period of
hours.19 The short experimental time and nature of
stimulus might, therefore, have accounted for the lack
of change in the levels of these molecules. L-selectin is,
however, normally rapidly released after leukocyte
stimulation,19 but changes in the levels of this molecule
may have been masked by the effects of the surgery.
We plan to use this model to study the effects of
low thrombin doses on the morphology and secreto-
ry activity of the endothelium and to examine the
early cellular interactions that take place when flow is
reduced. We also plan to examine the differences in
thrombus generation induced by other procoagulant
stimuli, eg, tissue factor and factor VIIa. Finally, we
would like to investigate the effects of different adhe-
sion molecule blocking strategies on thrombosis.
The model described is an ethically acceptable,
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simple, and reproducible means of inducing venous
thrombus formation in flowing blood in humans. It
may be of value in the study of the early cellular inter-
actions that lead to venous thrombogenesis. This
model may also be useful in testing the effectiveness
of novel antithrombotic agents, because substances
that are injected into the experimental vein do not
enter the circulation. Its application is, however,
restricted by the length of time in which observations
can be made, and studies on thrombus organization
and resolution are, therefore, not possible.
We thank the British Heart Foundation for funding
this study and Mr Ken Brady and the staff of the Electron
Microscopy Unit at Guy’s Hospital, London, for their
technical assistance. 
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